ATLAS4D Molecular Therapeutics (FDMT) earnings date: Nov 9, 2026
4D Molecular Therapeutics (FDMT) reports earnings for the quarter ended Sep 30, 2026 on Mon, Nov 9, 2026. Analysts expect EPS of -$1.03.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on FDMT
| Last price | $11.28 (-5.3%) |
|---|---|
| Normal 1-day range (±1σ) | ±4.7% |
| Earnings beat history | Beat the EPS estimate in 2 of the last 5 reports |
These figures come from the same calibrated model and valuation as the 4D Molecular Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
4D Molecular Therapeutics reports on Nov 9, 2026. One email the day before, with ATLAS’s read on 4D Molecular Therapeutics. You can switch it off at any time.
Alert me before FDMT reportsFree to start. Creating an account takes under a minute.
Notify me when 4D Molecular Therapeutics reports
Track FDMT free Add 4D Molecular Therapeutics to a free ATLAS watchlist and see its next report date in one place.
FDMT earnings at a glance
| Next report (confirmed) | Mon, Nov 9, 2026 |
|---|---|
| Time | Not stated |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$1.03 |
| Last report | Aug 13, 2026 · In line |
| Beat rate (last 5 reports) | 2 of 5 (40%) |
| Average EPS surprise | +54.3% |
| Average move around a report | ±5.1% (last 5) |
| Sector | Healthcare · Biotechnology |
4D Molecular Therapeutics earnings history: last 5 reports
4D Molecular Therapeutics last reported on Aug 13, 2026: EPS of -$1.04 against an estimate of -$1.02 (-2.0% surprise), in line with the estimate.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 13, 2026 | -$1.02 | -$1.04 | -2.0% | In line | +2.7% |
| May 7, 2026 | -$1.00 | -$1.01 | -1.0% | In line | -2.7% |
| Apr 16, 2026 | $1.15 | $1.15 | 0.0% | In line | +7.4% |
| Mar 18, 2026 | -$0.53 | $0.43 | +181.1% | Beat | +4.3% |
| Feb 6, 2026 | $3.18 | $6.15 | +93.4% | Beat | +8.2% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for FDMT
See the fair value, the probability range and the earnings history of 4D Molecular Therapeutics on its ATLAS page.
4D Molecular Therapeutics (FDMT) stock analysisPlans from €3.99 a month.
4D Molecular Therapeutics earnings: frequently asked questions
When does 4D Molecular Therapeutics (FDMT) report earnings?
4D Molecular Therapeutics is scheduled to report on Monday, November 9, 2026 (the time of day has not been stated). ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for FDMT?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$1.03 per share (USD). Estimates can change before the report.
How often does FDMT beat earnings estimates?
Of its last 5 reports with a recorded result, 4D Molecular Therapeutics beat the EPS estimate 2 times; the average surprise was +54.3%. Past results do not predict the next one.
How much does FDMT move around earnings?
Over its last 5 reports the stock moved an average of 5.1% (absolute, from the close before the report day to the close after it), and finished higher 4 of 5 times.
Did 4D Molecular Therapeutics beat earnings estimates last quarter?
4D Molecular Therapeutics last reported on Aug 13, 2026: EPS of -$1.04 against an estimate of -$1.02 (-2.0% surprise), in line with the estimate.
How much does FDMT usually move in a day?
On a normal trading day the ATLAS model puts FDMT’s one-day range at about ±4.7%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Mon, Nov 9, 2026
Educational information, not investment advice. Disclaimer